MetaVia is developing DA-1726, a dual oxyntomodulin analog agonist for obesity, and DA-1241, a GPR119 agonist for Metabolic Dysfunction-Associated Steatohepatitis (MASH), utilizing targeted receptor activation to enhance weight loss and improve liver health. These therapies aim to address the rising prevalence of cardiometabolic diseases by promoting weight loss, reducing liver inflammation, and improving glucose metabolism.
Funding
Funding not disclosed
Founders
Product
Problem
Obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) are increasingly prevalent cardiometabolic diseases with limited effective treatment options. Current therapies often fail to adequately address both weight management and liver health, leaving a significant unmet need for targeted interventions.
Solution
MetaVia is developing two novel drug candidates: DA-1726, a dual oxyntomodulin analog agonist for obesity, and DA-1241, a GPR119 agonist for MASH. DA-1726 functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist, administered via once-a-week injection, decreasing food intake and increasing energy expenditure for superior weight loss. DA-1241 promotes the release of key gut peptides GLP-1, GIP, and PYY, demonstrating positive effects on liver inflammation, lipid metabolism, weight loss, and glucose metabolism. These therapies aim to provide targeted receptor activation to enhance weight loss, reduce liver inflammation, and improve glucose metabolism.
Target Audience
The primary target audience includes individuals with obesity and patients diagnosed with Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Features
- DA-1726: Dual GLP1R/GCGR agonist administered via once-a-week injection
- DA-1726: Mimics the effects of the naturally-occurring gut hormone oxyntomodulin (OXM)
- DA-1241: GPR119 agonist that promotes the release of GLP-1, GIP, and PYY
- DA-1241: Demonstrated reduction in hepatic steatosis, hepatic inflammation, and liver fibrosis in preclinical studies
- DA-1241: Showed improvement in glucose control in preclinical studies